Menu

Category: Partner News

Critical Path Institute and TGen Forge Partnership to Advance TB Research

C-Path and the Translational Genomics Research Institute (TGen) are excited to announce a new partnership to sequence at least 12,000 tuberculosis (TB) bacteria isolates from around the world.

May 1, 2017 Partner News RDST Assay Development diagnostics drug resistance next-generation sequencing ReSeq TB ReseqTB

TB-PACTS Initiative Accepting Requests for Access

The TB-PACTS initiative represents a collaborative partnership between the Special Programme for Research and Training in Tropical Disease (TDR), the TB Alliance, St. George’s University of London, and Critical Path Institute (C-Path). The TB-PACTS data platform is designed to catalyze and accelerate innovative tuberculosis (TB) research by making aggregated Phase III TB clinical trial data […]

October 24, 2016 Drug Development Partner News Research Resources clinical trials drug development fluroquinolones TB-PACTS

CPTR and SIMCYP launch models to evaluate exposure and efficacy of TB drugs in combination

The Critical Path to TB Drug Regimens (CPTR) Initiative and SIMCYP have partnered to develop a TB-specific set of models and compound files to inform the design of first-in-human trials that will simultaneously evaluate the exposure and efficacy of novel anti-TB combination regimens of up to 4 drugs. This collection of models is comprised of: […]

October 1, 2016 Drug Development Partner News clinical trials Disease-Modeling drug development

New TB Clinical Trial Data-Sharing Platform Available for Researchers

TUCSON, Ariz., April 18, 2016 — The Critical Path Institute (C-Path), the Special Programme for Research and Training in Tropical Diseases (TDR), TB Alliance, andSt. George’s, University of London, are pleased to announce the launch of the TB-Platform for Aggregation of Clinical TB Studies (TB-PACTS). “TB-PACTS is a valuable tool in the fight against the […]

April 18, 2016 Drug Development Partner News Press Releases Regulatory Science Research Resources Uncategorized clinical trials drug development TB-PACTS

TB and HIV Join Together for Combined Community Engagement Forum

The following was authored by Stacey Hannah and Jessica Handibode, and re-posted from Avac.org We sang. We danced. We shared our experiences, and we learned from each other. Most importantly, we strategized as equals about how to promote the work of community engagement in clinical trials. And for the first time, engagement implementers from both TB […]

December 21, 2015 Partner News Research Resources Commununity engagement TB/HIV

TB Alliance Advances Next-Generation TB Drug Candidate into Clinical Testing

TBA-354 is the first potential tuberculosis drug to advance toPhase 1 trial in six years TB Alliance has announced the start of the first human trial of a new tuberculosis (TB) drug candidate, designated TBA-354. It is the first new TB drug candidate to begin a Phase 1 clinical trial since 2009. “There is a […]

February 19, 2015 Drug Development Partner News clinical trials drug development

International partnership to create global TB data-sharing platform

Recognizing an international need for a centralized, standardized data resource for globally diverse genomic and other clinically relevant tuberculosis data, the Critical Path to TB Drug Regimens (CPTR) initiative has begun development and implementation of a Rapid Drug Susceptibility Test (RDST) data-sharing platform in partnership with the Critical Path Institute (C-Path), FIND, the New Diagnostics […]

January 26, 2015 Partner News Press Releases

New Tuberculosis Drug Regimen Will Move to Landmark Phase 3 Clinical Trial

STAND trial will test the first regimen designed to significantly shorten and simplify the treatment of drug-sensitive and drug-resistant TB SEATTLE (April 23, 2014)—Based on positive results from earlier clinical studies, TB Alliance is advancing the first-ever drug regimen designed to treat both drug-sensitive and some forms of multi-drug resistant tuberculosis (TB) to a global […]

April 23, 2014 Partner News Press Releases

Critical Path Institute Receives Grant to Accelerate Development of Tuberculosis Treatments

Multi-year grant brings together non-profits, government, academia and the pharmaceutical industry to study pressing public health challenge TUCSON, Ariz., Feb. 4, 2014 /PRNewswire-USNewswire/ — The Critical Path Institute, an independent, non-profit that catalyzes innovative ideas that accelerate the speed of drug and medical product development, today announced it has received a three-year grant from the […]

February 10, 2014 Partner News

FDA approves bedaquiline for TB treatment; first new drug in 40 years

In late December, the US FDA approved bedaquiline for the treatment of MDR-TB on top of the current background regimen. Dr. Chrispin Kambili, an infectious disease specialist at Janssen, recently discussed their research on bedaquiline and reviewed plans for additional research testing on the drug at the 3rd Annual CPTR Workshop this past fall. Bedaquiline is […]

January 10, 2013 Partner News